Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma

Exclusion Criteria

• •1. Hepatitis B Virus (HBV) Infection:
• •HBsAg-positive with HBV DNA \>1×10³ copies/mL (patients with controlled viremia \[\<1×10³ copies/mL\] after antiviral therapy are eligible).
• •2. Hepatitis C Virus (HCV) Infection: Anti-HCV antibody-positive.
• •3. HIV/AIDS: Anti-HIV antibody-positive or diagnosed with acquired immunodeficiency syndrome (AIDS).
• •4. Active Tuberculosis (TB): History of active TB within the past year (regardless of treatment status). Exception: Patients with adequately treated past TB (confirmed by standard anti-TB therapy) may be enrolled if \>1 year since completion of treatment.
• •5. Active Autoimmune Diseases:Known or suspected autoimmune disorders (e.g., uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, or asthma requiring bronchodilators).
• •Exceptions:
• •Type 1 diabetes mellitus Hypothyroidism managed with hormone replacement Skin conditions not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia).
• •6. Interstitial Lung Disease (ILD):
• •History of ILD or pneumonitis requiring oral/IV steroids within the past year.
• •7. Immunosuppressive Therapy:
• •Chronic systemic corticosteroids (≥10 mg prednisone equivalent/day) or other immunosuppressants within 4 weeks prior to enrollment. Inhaled/topical steroids are permitted.
• •8. Uncontrolled Cardiac Disease: Heart failure (NYHA class ≥2), Unstable angina, Myocardial infarction within the past year, Clinically significant arrhythmias requiring treatment.
• •9. Pregnancy/Lactation: Pregnant or breastfeeding women (urine/blood pregnancy test required for women of childbearing potential).
• •10. Concurrent Malignancies:
• •History of other malignancies except:
• •Adequately treated non-melanoma skin cancer, Carcinoma in situ of the cervix, Papillary thyroid carcinoma.
• •11. Hypersensitivity: Known allergy to any component of the study drugs or excipients.
• •12. Active Infections:
• •Systemic infections requiring treatment within 1 week prior to enrollment.
• •Live Vaccines:
• •13. Administration of live vaccines within 30 days before the first immunotherapy dose.
• •14. Organ Transplantation: History of allogeneic organ transplantation.
• •15. Other High-Risk Conditions:
• •Any condition that may compromise patient safety or compliance per investigator assessment (e.g., severe psychiatric disorders, life-threatening comorbidities, or social/familial risk factors).